Search

Your search keyword '"Lo, Man Wai"' showing total 159 results
Start Over Author "Lo, Man Wai"
159 results on '"Lo, Man Wai"'

3. Evaluation of the relationship between cardiac calcification and cardiovascular disease using the echocardiographic calcium score in patients undergoing peritoneal dialysis: a cross-sectional study

Author

Sin, Ho-Kwan, primary, Wong, Ping-Nam, additional, Lo, Kin-Yee, additional, Lo, Man-Wai, additional, Chan, Shuk-Fan, additional, Lo, Kwok-Chi, additional, Wong, Yuk-Yi, additional, Ho, Lo-Yi, additional, Kwok, Wing-Tung, additional, Chan, Kai-Chun, additional, Wong, AndrewKui-Man, additional, and Mak, Siu-Ka, additional

Published
2023
Full Text
View/download PDF

6. An Echocardiography‐derived Calcium Score as a Predictor of Major Adverse Cardiovascular Events in Peritoneal Dialysis Patients – A Prospective Cohort Study

Author

Sin, Ho‐Kwan, primary, Wong, Ping‐Nam, additional, Lo, Kin‐Yee, additional, Lo, Man‐Wai, additional, Chan, Shuk‐Fan, additional, Lo, Kwok‐Chi, additional, Wong, Yuk‐Yi, additional, Ho, Lo‐Yi, additional, Kwok, Wing‐Tung, additional, Chan, Kai‐Chun, additional, Wong, Andrew Kui‐Man, additional, and Mak, Siu‐Ka, additional

Published
2021
Full Text
View/download PDF

7. Treatment of Severe Tumoral Calcinosis with Teriparatide in a Dialysis Patient after Total Parathyroidectomy

Author

Sin, Ho-Kwan, Wong, Ping-Nam, Lo, Kin-Yee, Lo, Man-Wai, Chan, Shuk-Fan, Lo, Kwok-Chi, Wong, Yuk-Yi, Ho, Lo-Yi, Kwok, Wing-Tung, Chan, Kai-Chun, Wong, Andrew Kui-Man, and Mak, Siu-Ka

Subjects
Article Subject
Abstract

Tumoral calcinosis is a rare but debilitating condition that can affect dialysis patients. Optimal management is largely unknown. We report the clinical course, treatment, and outcome of a peritoneal dialysis (PD) patient who developed tumoral calcinosis refractory to conventional treatment but improved with teriparatide therapy. A 26-year-old lady on PD for 2 years presented to us with tumoral calcinosis involving bilateral hands. Response to surgical excision, parathyroidectomy, and conversion to hemodialysis failed to result in sustained remission, and tumoral calcinosis progressed. After total parathyroidectomy, the patient had transient but partial remission in which her calcinosis deposits remained but were asymptomatic without pain or clinical signs of inflammation. However, she later experienced a relapse with involvement of the left elbow, right shoulder, right hip, and right thigh. Tumoral calcinosis remained uncontrolled resulting in debilitation, likely attributable to poor calcium and phosphate control because of adynamic bone disease after parathyroidectomy despite treatment of superimposed tuberculosis and therapy with sodium thiosulphate and pamidronic acid. Clinical improvement was however evident after the use of teriparatide. Asymptomatic hypocalcemia occurred after teriparatide therapy but resolved after 2 months. In conclusion, teriparatide appears to be useful for treating tumoral calcinosis in the presence of adynamic bone disease. Hypocalcemia can occur in the initial months of therapy.

Published
2021
Full Text
View/download PDF

12. An echocardiography‐derived calcium score as a predictor of major adverse cardiovascular events in peritoneal dialysis patients—A prospective cohort study.

Author

Sin, Ho‐Kwan, Wong, Ping‐Nam, Lo, Kin‐Yee, Lo, Man‐Wai, Chan, Shuk‐Fan, Lo, Kwok‐Chi, Wong, Yuk‐Yi, Ho, Lo‐Yi, Kwok, Wing‐Tung, Chan, Kai‐Chun, Wong, Andrew Kui‐Man, and Mak, Siu‐Ka

Subjects
MAJOR adverse cardiovascular events, PERITONEAL dialysis, HEMODIALYSIS patients, COHORT analysis, LONGITUDINAL method
Abstract

Background: An echocardiography‐derived calcium score (ECS) has been shown to predict cardiovascular (CV) mortality in the general population but has not been utilized in the dialysis population. Methods: We conducted a prospective cohort study including 125 prevalent PD patients. Two blinded and independent echocardiographers determined the ECS for each subject at baseline. The primary outcome was the three‐point major adverse cardiovascular events (MACE) which is a composite outcome comprising CV death, non‐fatal myocardial infarction and non‐fatal stroke. The secondary outcome was all‐cause mortality. Results: The mean age was 61 ± 13 years. The median follow‐up duration was 40 months (range 1–50). Seventy six (60.8%) of the subjects had diabetes mellitus (DM). The median duration of dialysis was 32 (IQR 16–54) months. The incidences of MACE and all‐cause mortality were 13.0 per 100 patient‐years and 18.3 per 100 patient‐years. Multivariate Cox regression analysis identified the following three independent predictors of MACE: ECS (HR 1.253/unit increase in ECS, 95% CI 1.014–1.547, p =.036), DM (HR 2.467, 95% CI 1.014–6.005, p =.047) and pre‐existing cardiovascular disease (CVD) (HR 2.441, 95% CI 1.261–4.728, p =.008); and the following two predictors of all‐cause mortality: pre‐existing CVD (HR 2.156, 95% CI 1.251–3.714, p =.006) and serum albumin (HR 0.887/g/L increase in serum albumin, 95% CI 0.839–0.937, p <.001). Conclusion: The ECS appears to be a significant predictor of MACE in PD patients independently of DM and pre‐existing CVD. SUMMARY AT A GLANCE: Increased echocardiography‐derived calcium score was associated with a significantly higher risk of major adverse cardiovascular events in 125 patients undergoing peritoneal dialysis, suggesting that this modality of investigation may be useful in cardiovascular risk stratification. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone – Results of a Randomized Open-Label Controlled Trial

Author

Wong, Ping-Nam, primary, Tong, Gensy M. W., additional, Wong, Yuk-Yi, additional, Lo, Kin-Yee, additional, Chan, Shuk-Fan, additional, Lo, Man-Wai, additional, Lo, Kwok-Chi, additional, Ho, Lo-Yi, additional, Tse, Cindy W. S., additional, Mak, Siu-Ka, additional, and Wong, Andrew K. M., additional

Published
2016
Full Text
View/download PDF

31. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism.

Author

Lo-Yi Ho, Ping-Nam Wong, Ho-Kwan Sin, Yuk-Yi Wong, Kwok-Chi Lo, Shuk-Fan Chan, Man-Wai Lo, Kin-Yee Lo, Siu-Ka Mak, Wong, Andrew Kui-Man, Ho, Lo-Yi, Wong, Ping-Nam, Sin, Ho-Kwan, Wong, Yuk-Yi, Lo, Kwok-Chi, Chan, Shuk-Fan, Lo, Man-Wai, Lo, Kin-Yee, and Mak, Siu-Ka

Subjects
BONE diseases, PARATHYROIDECTOMY, HYPERPARATHYROIDISM, PARATHYROID hormone, PREOPERATIVE care, CALCIUM metabolism, TREATMENT of chronic kidney failure, DIPHOSPHONATES, THERAPEUTIC use of vitamin D, CHRONIC kidney failure complications, DIETARY calcium, PHOSPHATE metabolism, ADRENALECTOMY, ALKALINE phosphatase, HEMODIALYSIS, HYPOCALCEMIA, SURGICAL complications, TREATMENT effectiveness, RETROSPECTIVE studies, THERAPEUTICS
Abstract

Background: Hungry bone syndrome (HBS) is an important postoperative complication after parathyroidectomy for severe secondary hyperparathyroidism (SHPT). There is, however, little data in the literature on its detailed clinical course, and the associated risk factors remain controversial.Methods: We did a single-center retrospective study on 62 consecutive dialysis patients who underwent total parathyroidectomy for SHPT to examine the risk factors, clinical course and outcome. Data on demographic characteristics, perioperative laboratory parameters including serum calcium, phosphate, alkaline phosphatase (ALP) and parathyroid hormone (PTH), drug treatment for SHPT and operative details of parathyroidectomy were collected.Results: Seventeen (27.4%) patients developed severe postoperative hypocalcemia with HBS. The serum calcium dropped progressively while serum ALP rose after operation until 2 weeks later when serum calcium reached the trough and serum ALP peaked. Serum phosphate also fell but stabilized between 4 and 14 days. The total postoperative calcium and vitamin D supplementation was significantly larger, and hospital stay was significantly longer in the group with HBS as compared with those without HBS. Young age, high body weight, high preoperative ALP level, and low preoperative calcium level independently predicted the development of HBS while preoperative PTH and use of cinacalcet or paricalcitol did not.Conclusion: HBS was common after total parathyroidectomy in patients with SHPT, and it is important to closely monitor the postoperative serum calcium, phosphate and ALP levels in the following 2 weeks, especially for those at risk. The implications of our findings on perioperative management are discussed. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. Persistent Sterile Peritoneal Inflammation after Catheter Removal for Refractory Bacterial Peritonitis Predicts Full-Blown Encapsulating Peritoneal Sclerosis

Author

Wong, Yuk-Yi, primary, Wong, Ping-Nam, additional, Mak, Siu-Ka, additional, Chan, Shuk-Fan, additional, Cheuk, Yuen-Yi, additional, Ho, Lo-Yi, additional, Lo, Kin-Yee, additional, Lo, Man-Wai, additional, Lo, Kwok-Chi, additional, Tong, Gensy Mei-Wah, additional, and Wong, Andrew Kui-Man, additional

Published
2013
Full Text
View/download PDF

38. Tirofiban (Aggrastat®)

Author

Cook, Jacquelynn J., primary, Bednar, Bohumil, additional, Lynch, Joseph J., additional, Gould, Robert J., additional, Egbertson, Melissa S., additional, Halczenko, Wasyl, additional, Duggan, Mark E., additional, Hartman, George D., additional, Lo, Man-Wai, additional, Murphy, Gail M., additional, Deckelbaum, Lawrence I., additional, Sax, Frederick L., additional, and Barr, Eliav, additional

Published
2006
Full Text
View/download PDF

43. PhRMA Perspective on Population and Individual Bioequivalence

Author

Barrett, Jeffrey S., primary, Batra, Vijay, additional, Chow, Andrew, additional, Cook, Jack, additional, Gould, A. Lawrence, additional, Heller, Allen H., additional, Lo, Man‐Wai, additional, Patterson, Scott D., additional, Smith, Brian P., additional, Stritar, Jeffrey A., additional, Vega, Jose M., additional, and Zariffa, Névine, additional

Published
2000
Full Text
View/download PDF

44. Update to the PhRMA Perspective on Population and Individual Bioequivalence

Author

Barrett, Jeffrey S., primary, Batra, Vijay, additional, Chow, Andrew, additional, Cook, Jack, additional, Gould, A. Lawrence, additional, Heller, Allen H., additional, Lo, Man-Wai, additional, Patterson, Scott D., additional, Smith, Brian P., additional, Stritar, Jeffrey A., additional, Vega, Jose M., additional, and Zariffa, Névine, additional

Published
2000
Full Text
View/download PDF

48. The pharmacokinetics of losartan in renal insufficiency

Author

Ska, Domenic A., primary, Lo, Man-Wai, additional, Shaw, Wayne C., additional, Keane, William F., additional, Gehr, Todd W.B., additional, Halstenson, Charles E., additional, Lipschutz, Katherine, additional, Furtek, Christine I., additional, Ritter, Michael A., additional, and Shahinfar, Shahnaz, additional

Published
1995
Full Text
View/download PDF

49. Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients

Author

Goldberg, Michael R., primary, Bradstreet, Thomas E., additional, McWilliams, Edward J., additional, Tanaka, Wesley K., additional, Lipert, Stephanie, additional, Bjornsson, Thorir D., additional, Waldman, Scott A., additional, Osborne, Barbara, additional, Pivadori, Lisa, additional, Lewis, George, additional, Blum, Robert, additional, Herman, Theodore, additional, Abraham, Paul A., additional, Halstenson, Charles N., additional, Lo, Man-Wai, additional, Lu, Hannah, additional, and Spector, Reynold, additional

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results